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We previously demonstrated in the Chinese macaque model that an oral vaccine made 
of inactivated SIV and Lactobacillus plantarum induced CD8+ regulatory T-cells, which 
suppressed the activation of SIV+CD4+ T-cells, prevented SIV replication, and protected 
macaques from SIV challenges. Here, we sought whether a similar population of CD8+ 
T-regs would induce the suppression of HIV replication in elite controllers (ECs), a small 
population (3‰) of HIV-infected patients with undetectable HIV replication. For that pur-
pose, we investigated the in vitro antiviral activity of fresh CD8+ T-cells on HIV-infected 
CD4+ T-cells taken from 10 ECs. The 10 ECs had a classical genomic profile: all of 
them carried the KIR3DL1 gene and 9 carried at least 1 allele of HLA-B:Bw4-80Ile (i.e., 
with an isoleucine residue at position 80). In the nine HLA-B:Bw4-80Ile-positive patients, 
we demonstrated a strong viral suppression by KIR3DL1-expressing CD8+ T-cells that 
required cell-to-cell contact to switch off the activation signals in infected CD4+ T-cells. 
KIR3DL1-expressing CD8+ T-cells withdrawal and KIR3DL1 neutralization by a specific 
anti-killer cell immunoglobulin-like receptor (KIR) antibody inhibited the suppression of 
viral replication. Our findings provide the first evidence for an instrumental role of KIR-
expressing CD8+ regulatory T-cells in the natural control of HIV-1 infection.
Keywords: aiDs, elite controllers, cD4+ T-cells, suppressive/regulatory cD8+ T-cells, nK cells, hla-B: 
Bw4-80ile gene, Kir3Dl1-expressing cD8+ T-cells, hiV-1 suppression assay
inTrODUcTiOn
The success of antiviral vaccines developed over the past decades generally depends on their ability 
to mimic a protective immunity similar to that induced by natural infection. In this context, an 
improved understanding of the host factors associated with the natural control of viral replication 
in elite controllers (ECs), a small group (3‰) of HIV-1 infected patients with long-term natural 
control of their viral replication (1), would potentially provide important information relevant for 
the development of new vaccines against HIV.
So far, the immunological features conferring protection against HIV in ECs have remained 
largely unknown. Specific HLA class I-B alleles (including HLA B27 and B57), gathered under 
the serological HLA-Bw4 motif, have been reported to be constantly associated with a favorable 
outcome of HIV-1 infection (2–4). This genetic association is in agreement with the immunogenetic 
understanding that epistatic interactions between killer cell immunoglobulin-like receptors (KIRs) 
and their cognate HLA-I ligands determine the outcome of viral  infections and susceptibility to 
autoimmune diseases and cancer (5–7).
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HLA-B molecules display one of two mutually exclusive sero-
logical epitopes, Bw4 and Bw6, which are identified on the basis 
of five variable amino acids at positions 77 and 80–83 (8). About 
two thirds of all HLA-B molecules express Bw6, whereas Bw4 is 
present in the remaining third and in several HLA-A molecules. 
The HLA-Bw4 motif, which is expressed by leukocytes, includ-
ing CD4+ T-cells, the principal target of HIV, is a ligand of KIRs 
(5, 9). KIRs constitute a polygenic and polymorphic family of 
receptors, with both inhibiting and activating motifs (10) that are 
expressed by NK cells (11) and T cells (12–15), and participate 
in both innate and adaptive immunity. NK cells were reported 
to inhibit HIV-1 replication in CD4+ T-cells in a HLA-B:Bw4-
80Ile (i.e., with an isoleucine (Ile) residue at position 80) and 
KIR3DS1- or KIR3DL1-dependent manner (16, 17). Inhibition 
of viral replication by NK cells, most likely involved in the initial 
viral control of primary HIV-1 infection, is however modest (18, 
19). Surprisingly, little information is available on the role of KIR-
expressing CD8+ T-cells in the containment of HIV-1 replication 
during the natural course of the infection. Here, we investigated 
the role of KIR-expressing CD8+ T-cells in the control of viral 
replication in CD4+ T-cells of 10 HIV-1-infected ECs and exam-
ined its association with either amino acid polymorphism of HLA 
alleles or KIR genotype. Ten untreated patients with high viral 
load (HVLpts) and two healthy donors (HDs) served as controls. 
We found that fresh KIR3DL1-expressing CD8+ T-cells from 9 
out of the 10 examined ECs were capable of strongly suppressing 
HIV-1 replication in HIV-1-infected CD4+ T-cells carrying an 
HLA-B:Bw4-80Ile motif.
MaTerials anD MeThODs
Patients
Ten ECs with an undetectable plasma viral load (<50 copies/ml) for 
≥10 years and 10 HIV-1-infected HVLpts (>104  copies/ml) (Table 
S1 in Supplementary Material) were recruited from a cohort of 
untreated individuals infected with HIV-1 CRF01_AE subtype at 
the CDC of Xishuangbanna (Yunnan, China) (20, 21). The study 
was approved by the institutional review boards of the Tropical 
Medicine Institute, Guangzhou University of Chinese Medicine. 
Informed consent was obtained at the study sites from all patients.
hla and Kir genotyping
Genomic DNA was extracted from whole PBMCs and was typed 
for both HLA class I and KIR alleles. HLA class I genotyping 
was performed by a commercial sequencing service (Bioassay 
Laboratory of Capital Bio Corporation, Beijing, China). KIR 
genotyping was performed by using a multiplex PCR–sequence-
specific priming (SSP) protocol, as previously described (22). 
Two sets of primers were designed for each of the 16 KIR genes, 
and the presence of the gene was detected only when both were 
amplified.
Viral load
HIV-1 RNA (copies per milliliter) measurements determined 
previously by a commercial kit (Real-time HIV-1, Abbott, USA) 
were available for analysis. To exclude the potential underestima-
tion of viral load caused by sequence mismatch with any given 
primer/probe set, the undetectable viral load (<50 copies/ml) of 
ECs was confirmed by an ultrasensitive detection system with 
multiple primer/probe sets (23).
Flow cytometry
Commercially available monoclonal antibodies (mAbs) against 
the following proteins were used: CD3, CD4, CD8, CD16, CD56, 
KIR2DL1 (clone REA284), KIR2DL2/2DL3 (clone DX27), 
KIR3DL1/3DL2 (clone 5.133), KIR3DL1 (clone Dx9), KIR2DS4 
(clone JJC11.6), and KIR3DS1 (clone z27).
hiV-1 suppression assay
CD4+ T cells from each individual were purified by magnetic 
positive labeling (Microbeads, Miltenyi Biotec GmbH, Bergisch 
Gladbach, Germany) and then acutely infected with a clinical 
HIV-1M subtype B isolate (10−3 multiplicity of infection) in the 
presence or absence of negatively purified (Microbeads, Miltenyi 
Biotec) CD8+ T cells (>90% purity) at a CD4/CD8 ratio of 1:3, 
and then stimulated with SEB (0.5 μg/ml) and CD3 (5 μg/ml)/
CD28 (2 μg/ml) antibodies for 16 h. After washing, the cells were 
cultured in quadruplicates in 96-well plates. Cultures were main-
tained in a final volume of 200 μl per well of RPMI 1640 medium 
containing 100  IU of human rIL2 (Roche Diagnostics GmbH, 
Mannheim, Germany) for 5 days. Viral loads were measured by a 
real-time RT-PCR (see above) in culture supernatants collected at 
day 5. The suppression assay was standardized to produce around 
107 (ranging from 3 ×  106 to 3 ×  107) HIV-1 RNA copies per 
milliliter in the 5-day culture (quadruplicates) of activated CD4+ 
T cells alone. The fold of viral suppression was determined as 
the geometric means of viral concentration in the culture super-
natants from the infected CD4+ target cells only divided by the 
geometric means of viral concentration in the supernatants from 
cocultured CD8+ and CD4+ T cells. In some depletion experi-
ments, microbead-conjugated mAbs against CD8, NK (CD16/
CD56), KIR3DL1 (Dx9), and inhibitory pan-KIRs [cocktail 
antibodies for CD158a (KIR2DL1), CD158b (KIR2DL2/DL3), 
CD158f (KIR2DL5), and CD158e/k (KIR3DL1/DL2)] (Milteny 
Biotec) were used. Moreover, anti-KIR3DL1 (clone Dx9) and 
anti-KIR3DS1 (clone z27) (without Microbead conjugation) 
were added in the culture medium to perform neutralization 
experiments.
To validate the HIV-1 suppression assay, we performed the 
same assay with fresh PBMC samples taken from 30 healthy vol-
unteers. The CD8+ T-cell-mediated viral suppression observed in 
all healthy volunteers was <1 log HIV-1 RNA copies per milliliter 
(data not shown). Therefore, the sensitivity of our viral suppres-
sion assay is determined as a reduction of 1 log HIV-1 RNA copies 
per milliliter.
cell lysis assay
Both purified CD8+ T cells (effector cells) and purified CD4+ 
T cells (target cells) pulsed with 1010 aldrithiol-2-treated HIV-1 M 
subtype B isolate (24) were labeled with 40-nM 3,3′-dihexyloxac-
arbocyanine (DiOC6) (25) (Molecular Probes) for 10 min at 37°C. 
TaBle 1 | Bw4/Bw6 motifs in 10 elite controllers (ecs) and 10 patients with high viral load (hVlpts).
serological 
motifs
class i type and allelesa amino-acid position (numberb in ecs/hVlpts)
77 80 81 82 83
Bw4 HLA-A/B Asn (9/3)* Ile (9/1)** Ala (9/3)* Leu (9/3)* Arg (9/3)*
A*2402, B*1302, B*1513, B*2702, B*2704, B*3802, 
B*5101, B*5102, B*5201, B*5301, B*5801
Thr (0/2)
Bw6 HLA-B Ser (5/10)* Asn (5/10)* Leu (5/10)* Arg (5/10)* Gly (5/10)*
B*1501, B*1502, B*1512, B*1532, B*3505, B*4001, 
B*4002, B*4601, B*4801, B*5401, B*5502
*P < 0.05 (Fisher’s exact test was performed on the frequency comparison of single amino-acid position between ECs and HVLpts).
**P < 0.01.
aOnly alleles observed in the individuals who participated in the study.
bThe number of individuals (either homozygous or heterozygous for Bw4 or Bw6) showing a particular amino acid at each HLA-I position.
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Target cells were labeled with PerCP-Cy5-conjugated anti-CD4 
(BD Bioscience) for 20  min on ice. After washing three times, 
effector cells were mixed with target cells in a U-bottomed 96-well 
plate at different effector/target (E/T) ratios (3:1, 1:1, and 0.3:1) 
in triplicate. K562 cells (target) with APC-conjugated anti-CD32 
(BD Bioscience) and purified CD56+ (NK) cells (effector) from 
four HD were included as an assay control. After 4  h incuba-
tion at 37°C in the presence of SEB and anti-CD3/anti-CD28, 
cells were harvested and analyzed by flow cytometry. Percent 
cytotoxicity was calculated as follows: 100 × (% of total apoptotic 
target cells − % of spontaneous apoptotic target cells)/(100 − % 
of spontaneous apoptotic target cells).
statistical analysis
Impaired data between different groups of individuals were 
compared by the Fisher’s Exact Test or by the Mann–Whitney.
resUlTs
Most elite controllers have hla-B: 
Bw4-80ile and Kir3Dl1 genotypes
Clinical and biological characteristics of the 10 ECs and the 10 
HVLpts are summarized in Table S1 in Supplementary Material. 
All 20 untreated patients displayed a CD4+ T-cell count higher 
than 400/μl, a level that is not eligible for starting antiretroviral 
therapy in China.
Among the 10 ECs, 4 were homozygous for the serological 
motif Bw4 (No. 3, 5, 9, and 10), 5 were heterozygous for Bw4 and 
Bw6 (No. 1, 2, 4, 7, and 8), and the last 1 (No. 6) was homozy-
gous for the serological motif Bw6. In the nine ECs where the 
Bw4 motif was present (No. 1–5 and 7–10), it displayed an 
isoleucine residue at position 80 (HLA-B:Bw4-80Ile) (Table 1). 
In comparison, among the 10 HVLpts, 7 (No. 1, 3, 5–8, and 10) 
were homozygous for the Bw6 motif. The remaining three (No. 
2, 4, and 9) were heterozygous for the Bw6 and Bw4 serotypes 
among whom one (HVLpt No. 4) had the Bw4-80Ile motif and 
the remaining two (HVLpts No. 2 and 9) had a Bw4-80Thr motif 
(Table S2 in Supplementary Material).
Overall, three HLA alleles (HLA-B 45Thr, 80Ile, and HLA-A 
97Met) were significantly more frequent in ECs than in HVLpts 
(P < 0.01 for HLA-B 45Thr and 80Ile; P < 0.05 for HLA-A 97Met). 
One HLA allele (HLA-A 152Val) was significantly less frequent in 
ECs than in HVLpts (P < 0.05) (Figure 1A).
All 16 KIR genes (9 group A and 7 group B) were detected 
(Table  S3 in Supplementary Material). The KIR group A gene 
frequency was equally detected in ECs (average of 8.8 genes per 
person) and HVLpts (8.4 genes per person) (P =  ns), whereas 
the KIR group B genes were significantly more frequent in ECs 
(4.6 genes per person) than in HVLpts (2.2 genes per person) 
(P < 0.05).
The framework loci (KIR2DL4, KIR3DL2, and KIR3DL3) 
and pseudogenes (KIR2DP1 and KIR3DP1) were observed in 
all individuals of both groups of patients. Three inhibitory genes 
(KIR2DL2, KIR2DL5, and KIR3DL1) and two activating genes 
(KIR2DS2 and KIR2DS5) were more frequent in ECs than in 
HVLpts (P < 0.05) (Figure 1B). KIR3DL1 was carried by all 10 
ECs (9 of whom having at least 1 BW4-80Ile allele) and by 5 out 
of the 10 HVLpts (No. 2 who was Bw6/Bw4-80Thr and No. 3, 6, 
7, and 8 who were Bw6/Bw6).
cD8+ T-cells rather than nK cells 
strongly suppress hiV-1 replication  
In Vitro
To exclude any possible contamination of CD8+ T-cells by 
NK  cells, as NKT cells also express the CD8 molecule, CD8+ 
T-cells were purified from fresh PBMCs by deleting NK cells 
(CD16/CD56), monocytes (CD14), and B cells (CD19/CD20) 
using a mixture of microbead-conjugated mAbs.
Fresh CD8+ T-cells from the nine ECs possessing both the 
HLA-Bw4-80Ile motif and the KIR3DL1 gene exhibited a strong 
suppression of viral replication in autologous (superinfected) 
target CD4+ T-cells (>5-log reduction of viral RNA in culture 
supernatants). A much weaker (3 logs) CD8+ T-cell-dependent 
viral suppression was observed for EC No. 6, who, although car-
rying KIR3DL1, was homozygous for HLA-B: Bw6. In contrast, 
the suppression of viral replication caused by fresh CD8+ T-cells 
from the HVLpts remained at baseline levels (≤2 logs) in all cases 
(P < 0.001) (Figure 2A).
Non-depleted PBMC of five ECs (two homozygous and 
three heterozygote for HLA-B:Bw4-80Ile but all of them car-
rying KIR3DL1) cocultured with autologous (superinfected) 
CD4+ T-cells suppressed strongly HIV-1 replication (>5 logs). 
FigUre 2 | cD8+ T-cell (rather than nK cell)-mediated viral 
suppression in 10 elite controllers (ecs) and 10 patients with high 
viral load (hVlpts). (a) Suppression of HIV-1 replication in autologous 
CD4+ T cells by CD8+ T cells purified (by negative selection) from fresh 
PBMCs. (B) By fresh PBMCs depleted of CD8 or CD16/56.FigUre 1 | hla-i and Kir alleles frequencies; differences between 10 
elite controllers (ecs) and 10 patients with high viral load (hVlpts). (a) 
Two HLA-I B and one HLA-I A alleles were more frequent in ECs (green) than 
in HVLpts (red); only one HLA-A allele was more frequent in HVLpts than in 
ECs. (B) Five KIR alleles were more frequent in ECs (green) than in HVLpts 
(red). *P < 0.05; **P < 0.01.
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In contrast, upon depletion of CD8+ T-cells, the viral suppres-
sion capacity of PBMCs dropped to nearly baseline levels (≤2 
logs, P <  0.01). However, upon depletion of NK CD16+/56+ 
cells, viral suppression levels of PBMCs remained almost as high 
as that of non-depleted PBMC (P =  0.07) (Figure 2B). These 
data clearly indicate that CD8+ T-cells contribute in a much 
larger extent than NK cells to the inhibition of viral replication 
in vitro.
Functions of cD8+ T-cell-Mediated Viral 
suppression In Vitro
When freshly purified CD8+ T-cells (stimulated at the same time as 
target CD4+ T-cells with SEB and anti-CD3/anti-CD28 antibod-
ies) were added 48 h after the activation of HIV-1-superinfected 
CD4+ T-cells, viral suppression was much less effective (<3 logs) 
compared to that obtained when CD8+ T-cells were added before 
T-cell activation where viral suppression was maximum (>5 logs) 
(P < 0.05) (Figure 3A). This observation indicates that the inhibi-
tion of viral replication by CD8+ T-cells is more efficient when 
CD4+ T-cells are quiescent/not activated.
To investigate whether the viral suppressive effect of CD8+ 
T-cells would involve soluble factors or rather require cell-to-
cell contact, experiments were conducted in transwell culture 
chambers, in which target CD4+ T-cells were physically separated 
from effector CD8+ T-cells. Under these experimental conditions, 
the suppression of HIV-1 replication was strongly impaired 
(reaching only <3 logs), supporting the hypothesis that CD8+ 
T-cell-mediated viral suppression requires cell-to-cell contact 
(Figure 3B).
We next investigated whether CD8+ T-cell-mediated viral 
suppression would involve anti-CD4+ cytotoxic effects. A highly 
sensitive cytotoxicity assay (25) was used to detect cell lysis in 
coculture experiments mixing autologous CD8+ T-cells and HIV-1-
superinfected target CD4+ T-cells derived from five ECs (No. 1–5) 
and five HVLpts (No. 1–5). No lysis could be documented under 
these conditions (Figure 3C), indicating that the CD8-mediated 
viral suppression observed in ECs is most likely not cytolytic.
hla and Kir interaction in cD8+  
T-cell-Mediated Viral suppression
The molecular basis of viral suppression by autologous or alloge-
neic CD8+ T-cells carrying KIR3DL1 (but not KIR3DS1) genes 
was investigated in more details in four ECs with different HLA-B 
genotypes: ECs No. 1 and 2 were heterozygote Bw4-80Ile/Bw6, 
FigUre 3 | Functional features of cD8+ T-cell-mediated viral 
suppression. (a) CD8+ T-cell-mediated viral suppression (green) was 
reduced by nearly 3 logs when freshly purified CD8+ T cells were added 48 h 
after SEB and anti-CD3/28 stimulation (red). (B) CD8+ T-cell-mediated viral 
suppression (green) was reduced by 2.5 logs when CD8+ T cells were 
separated in a transwell culture (red). (c) No cytotoxicity was observed in 
autologous HIV-1-infected CD4+ T cells (target cells) co-incubated with CD8+ 
T-cells (effector cells) from ECs No. 1–5.
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EC No. 3 was homozygote Bw4-80Ile/Bw4-80Ile, while EC No. 6 
had no Bw4-80Ile allele (since this patient was homozygote Bw6/
Bw6). Superinfected CD4+ T-cells taken from these four ECs and 
from four HVLpts [No. 1 and 3: both homozygotes Bw6/Bw6, 
No. 2: heterozygote Bw6/Bw4-80Thr, and No. 4: Bw6/Bw4-80Ile 
(without a KIR3DL1 allele)] were used as targets. Two HDs car-
rying KIR3DL1 (but without KIR3DS1) and HLA-B Bw4-80Ile 
genes were included as control.
In ECs No. 1–3 (who carried at least one Bw4-80Ile allele and 
were KIR3DL1), the CD8+ T-cell-mediated viral suppression was 
very strong (5–6 logs) whether target CD4+ T-cells were autolo-
gous or allogeneic (Figure 4, left green bars), In contrast, CD8+ 
T-cells from the same EC No. 1–3 had a much lower suppressive 
activity (barely reaching 3 logs) on target CD4+ T-cells of EC 
No. 6 or on those of HVLpts No. 1–3 who did not carry Bw4-
80Ile (since they were Bw6/Bw6 or Bw6/Bw4-80Thr) (Figure 4, 
 middle, green bars). Moreover, as already shown (Figure 2A), the 
same low level of viral suppression was achieved when EC No. 6 
CD8+ T-cells were cocultured with their autologous target CD4+ 
T cells; EC No. 6 carried the KIR3DL1 gene but had no Bw4-80Ile 
allele (he was Bw6/Bw6). Interestingly, although EC No. 6 did 
carry the KIR3DL1 gene, his CD8+ T-cells also induced a low level 
of viral suppression when cocultured with HLA-B:Bw4-80Ile-
carrying target CD4+ T cells from ECs No. 1–3 (Figure 4, blue 
bar); a baseline (1 log) viral suppression was finally observed in 
HLA-B:Bw4-80Ile-carrying target CD4+ T cells cocultured with 
KIR3DL1-carrying CD8+ T-cells from HDs (Figure 4, red bars). 
On the other hand, a strong CD8+ T-cell-mediated viral suppres-
sion was observed with allogeneic target CD4+ T-cells of HVLpt 
No. 4 and of HDs No. 1 and 2, because all three individuals carried 
at least one Bw4-80Ile allele, while the effector CD8+ T-cells car-
ried the KIR3DL1 gene (Figure 4, right, green bars).
Kir3Dl1-expressing cD8+ T-cells 
responsible for hiV-1 suppression
Having observed the correlation between the combination of 
KIR3DL1 and HLA-B:Bw4-80Ile genes and HIV-1 suppression 
in  vitro and in  vivo, we further investigated the expression 
of KIRs on CD8+ T-cells in the 10 ECs (No. 1–10) and the 5 
HVLpts carrying KIR3DL1 (No. 2, 3, and 6–8). On average, the 
mean expression of all inhibitory KIRs (including KIR2DL1, 
KIR2DL2, KIR2DL3, KIR2DL5, KIR3DL1, and KIR3DL2, 
hereafter collectively referred as pan-KIR) in the CD8+ T-cells 
from the 10 ECs was 27.1% (range 9.2–45.7%). The expression of 
pan-KIR in the CD8+ T-cells from the 5 HVLpts (mean 10.3%, 
range 3.8–20.4%) was significantly lower (P < 0.05). The same 
was true for the expression of KIR3DL1 in the CD8+ T-cells from 
the 10 ECs (mean 8%, range 0.9–15.5%), a percentage signifi-
cantly higher than that observed in HVLpts (mean 2.2%, range 
0.5–5.7%, P < 0.05) (Figures 5A,B; Table S4 in Supplementary 
Material).
Due to the fact that only 8% (range 0.9–15.5%) of ECs’ CD8+ 
T-cells expressed KIR3DL1 at the cell membrane surface, it is 
very difficult to purify KIR3DL1-expressing CD8+ T-cells from 
such a small population (<3%) of PBMCs (which would have 
allowed to perform specific functional assays). Alternatively, 
we conducted viral suppression assays using fresh CD8+ T-cells 
from ECs (No. 1–5) depleted (or not) of KIR-expressing cells by 
microbead-conjugated mAbs against KIRs. CD8+ T-cell-mediated 
 suppression of HIV-1 replication in Bw4-80Ile-carrying CD4+ 
T-cells disappeared when effector CD8+ T-cells were depleted of 
either whole inhibitory KIRs or KIR3DL1 alone (Figure 5C).
In addition, we performed the viral suppression assay in 
the presence (or absence) of anti-KIR3DL1 or anti-KIR3DS1 
antibody to check whether the viral suppression was actually 
influenced by this receptor. CD8+ T-cell-mediated suppression of 
HIV-1 replication was suppressed by the anti-KIR3DL1 antibody 
(and not in the presence of an anti-KIR3DS1 antibody) in the 
five Bw4-80I/KIR3DL1-matched ECs (ECs#1–5) (Figure  5D, 
green bars); in contrast, the low levels of viral suppression 
observed in the three Bw4-80I/KIRD3L1-mismatched patients 
(EC#6, Bw4-80I−/KIR3DL1+; HVLpt#2, Bw4-80I−/KIR3DL1−; 
and HVLpt#4, Bw4-80I+/KIR3DL1−) were not modified by the 
presence of the anti-KIR3DL1 antibody (Figure 5D, red bars). 
These observations confirm the specificity of the anti-KIR3DL1 
FigUre 4 | association between cD8+ T-cell-mediated viral suppression and hla-B Bw4-80ile/KirsDl1 combined genotypes. For details, see Section 
“HLA and KIR Interaction in CD8+ T-Cell-Mediated Viral Suppression” in Section “Results.”
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antibody to block the suppression of HIV-1 replication observed 
in Bw4-80I/KIR3DL1-matched ECs. These data suggest that 
KIR3DL1-expressing CD8+ T-cells are effectively responsible for 
switching off the activation of HIV-1-infected HLA-B:Bw4-80Ile-
carrying CD4+ T-cells, thereby suppressing viral replication in 
superinfected target cells.
DiscUssiOn
Our data demonstrate that fresh inhibitory KIR3DL1-expressing 
CD8+ T cells from HIV-1-infected ECs inhibit virus replication 
in autologous or allogeneic HIV-1-infected Bw4-80Ile+ CD4+ 
T-cells. Although our observations cannot proof the existence 
of a single protein interaction between Bw4-80Ile and KIR3DL1, 
the deletion of KIR3DL1-expressing cells and the neutralization 
of KIR3DL1 by an anti-KIR3DL1 mAb strongly suggest the 
major role of the Bw4-80I/KIR3DL1 interaction in the control of 
viral replication by ECs’ CD8+ T-cells. This specific cooperation 
between effector and target cells seems to prevent CD4+ T-cell 
activation and results ultimately in the strong suppression of 
HIV-1 replication. Interestingly, in the context of the in vitro assay 
used in the present study, the cytotoxic role of CD8+ T-cells (26) 
is nil and that of suppressive soluble factors (27) appears likely 
marginal (Figures 3 and 4). Overall, these findings provide the 
first evidence for a pivotal role of Bw4-80Ile-restricted KIR3DL1-
expressing CD8+ T-cells in the natural control of HIV-1 replica-
tion in ECs, highlighting for the first time a mechanistic basis 
for the protective effect of combined Bw4-80Ile and KIR3DL1 
genotypes, which was reported in several studies of molecular 
epidemiology (2–4).
In healthy individuals, 5% (range 1–38%) of CD8+ T-cells 
express all inhibitory KIRs (pan-KIR) (12). In the present study, 
we observed that as high as 27.1% (range 9.2–45.7%) of CD8+ 
T-cells expressed the pan-KIR in ECs as compared to 10.3% 
(range 3.8–20.4%) in HVLpts (Figure  5B; P <  0.01). Of note 
is the fact that we detected the pan-KIR with mAbs specific for 
six inhibitory KIRs (KIR2DL1, KIR2DL2, KIR2DL3, KIR2DL5, 
KIR3DL1, and KIR3DL2), whereas the pan-KIR expression was 
previously analyzed using mAbs specific for only four inhibi-
tory KIRs (KIR2DL1, KIR2DL3, KIR3DL1, and KIR3DL2); the 
levels of pan-KIR staining should thus be higher in our study 
than in the previous report. The higher level of pan-KIR expres-
sion in ECs than in HVLpts could be explained partially by 
the observation that both KIR2DL2 and KIR2DL5 (exclusively 
included in our pan-KIR panel) genes were more frequent in 
ECs than in HVLpts (Figure  1B). However, although equally 
carrying KIR3DL1 gene, the expression of KIR3DL1 in CD8+ 
T-cells was significantly higher in ECs (8.9%) than in HVLpts 
(2.2%) (P <  0.05). This finding indicates that an expansion of 
KIR3DL1-expressing CD8+ T-cells triggered by HIV-1-infected 
HLA-B:Bw4-80Ile+CD4+ T-cells may occur during the natural 
course of HIV-1 infection in ECs.
NK cells have been shown to play a critical role in the initial 
containment of viral replication in several viral infections (28). 
The observation of their expansion during the acute phase of 
HIV-1 infection has suggested a potential role for the innate 
immune response in the initial control of HIV-1 replication (29). 
In this context, NK cells have been reported to inhibit HIV-1 
replication in an HLA-B Bw4-80Ile/KIR 3DS1- or KIR 3DL1-
dependent manner (16, 17). However, in ECs, the suppression of 
replication induced by CD8+ T-cells was shown to be more robust 
than that mediated by NK cells (18). Our study fully confirmed 
this observation: the viral suppression levels of PBMCs prede-
pleted of NK cells (CD16/CD56) was reduced only by 1 log as 
compared to bulk PBMCs (P = 0.07) in the same culture system 
(Figure 2B).
FigUre 5 | Kir3Dl1 expression on cD8+ T-cells is required for hla-B:Bw4-80ile-dependent viral suppression. (a) Cytometric analysis of KIR expression 
in CD8+ T-cells freshly taken from a representative EC (No. 3). (B) Pan-KIR (total inhibitory KIRs) and KIR3DL1-expressing CD8+ T-cells were significantly higher in 
ECs (No. 1–5) (green) than in HVLpts carrying KIR3DL1 gene (No. 2, 3, and 6–8). (c) CD8+ T-cell-mediated viral suppression was reduced by 4–5 logs when freshly 
pan-KIR or KIR3DL1-depleted CD8+ T-cells were added as compared with bulk CD8+ T-cells. (D) CD8+ T-cell-mediated viral suppression was reduced by 3–4 logs 
in Bw4-80I/KIR3DL1-matched patients (EC#1–5) when the anti-KIR3DL1 antibody (clone Dx9) was added as compared with parallel cultures in the presence of 
anti-KIR3DS1 antibody (clone z27) or medium alone. In contrast, the low levels of viral suppression observed in Bw4-80I/KIR3DL1-mismatched patients (EC#6, 
HVLpt#2, and HVLpt#4) remained unaffected by the anti-KIR3DL1 antibody (clone Dx9).
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From the observations reported here, we can conclude that 
the long-term containment of HIV-1 in ECs mostly relies on the 
combined presence in these patients of HIV-1-infected target 
CD4+ T-cells expressing Bw4-80Ile and of effector CD8+ T-cells 
expressing KIR3DL1. This finding is consistent with the dem-
onstration that KIR-expressing CD8+ T-cells are terminally dif-
ferentiated effectors with a restricted KIR repertoire dominated 
by a single KIR, the specificity of which is often distinct from that 
of the same patient’s NK cells (12). In addition, previous studies 
have also indicated that the engagement of inhibitory KIRs on 
CD8+ T-cells drives the accumulation of KIR+ memory CD8+ 
T-cells by downregulating activation-induced cell death (30, 31). 
Thus long-lived memory KIR-expressing CD8+ T-cells might 
exist as demonstrated for NKT cells (32). The moderate suppres-
sion of viral replication (almost 3 logs) observed in the HIV-1 
(CRF01_AE subtype)-infected EC No. 6 (Figure 2A), who was 
homozygous for the Bw6 serologic motif (HLA-B*4601/4801) 
(Table S2 in Supplementary Material), does not contradict the 
above conclusions, since some Bw6 alleles (such as HLA-B*14, 
HLA-B*4201, and HLA-B*8101) were also reported to be associ-
ated with delayed disease progression in individuals with HIV-1 
B and C subtypes (33). Here, the protection might involve other 
mechanisms, such as the recognition of immunodominant HIV-1 
peptides in the classical acquired immune response setting (34, 
35). Nevertheless, due to the limited number of available samples 
analyzed in the present study, definitive conclusions need to be 
confirmed in future studies with larger sample sizes.
The low suppression of viral replication (3 logs) observed 
both in transwell experiments (Figure 3B) and in mismatched 
cocultures of patients’ CD4 and CD8+ T-cells (Figure  4, green 
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bars of the middle panel and blue bars) remains to be explained. 
Such a low viral suppression stands, however, nearly 2 logs above 
the baseline suppression (1 log), observed in coculure of unin-
fected donors’ CD8+ T-cells together with patients’ CD4+ T-cells. 
Whether soluble factors may have a contribution in the overall 
viral suppression induced by KIR3DL1-expressing CD8+ T-cells 
remains to be explored. This phenomenon would however not 
be surprising since effector KIR3DL1-expressing CD8+ T-cells 
have been suggested to execute their suppressive activity through 
secretions of cytokines or chemokines as demonstrated for NK 
cells (28).
Although the stimulation of CD4+ T-cells with SEB and anti-
CD3/CD28 antibodies in our viral suppression assay may cause 
activation of CD8+ T-cells and thus improve their suppressive 
function (36), this cannot explain the results showing that the 
suppression was stronger when CD8+ T-cells were added before 
than after CD4+ T-cells stimulation with SEB and anti-CD3/
CD28 antibodies since CD8+ T-cells were always stimulated in 
parallel at the same time as CD4+ T-cells whether added before 
or after the activation of CD4+ T-cells. This observation suggests 
that the inhibition of viral replication by KIR3DL1-expressing 
CD8+ T-cells is much more efficient when target CD4+ T-cells 
carrying Bw4-80I gene are quiescent/not activated. In a previous 
study using autologous-infected CD4+ T-cells elimination as a 
measure of the suppressive activity of CD8+ T-cells, it was shown 
that activated CD8+ T-cells from ECs were capable to kill infected 
(P24+) CD4+ T-cells (36). This result is in contradiction with our 
observation that cell lysis was not detected in coculture experi-
ments mixing autologous CD8+ T-cells and HIV-1-superinfected 
target CD4+ T-cells derived from five ECs (No. 1–5) and five 
HVLpts (No. 1–5) (Figure  3C). This contradiction might be 
explained by the use of a laboratory-adapted HIV-1 strain 
(HIVSF162) with a high infection rate (>30% of CD4+ T-cells) in 
the abovementioned study (36), while it was a clinical HIV-1 
isolate with a much lower infection rate (<5%), which was used 
in the present study.
So far, immunological studies in HIV-1 infection have 
mainly focused on classical virus-specific cytotoxic T cells 
(CTLs) and antibody responses (26). Consequently, the goal 
of most HIV vaccines developed during the last two decades 
was to induce long-lived memory B and T cells capable of 
protecting the host from infection via the production of high-
affinity antibodies and/or CTLs (37). However, efforts aimed 
at stimulating such approaches to develop a vaccine against 
HIV-1 have been so far unsuccessful, possibly because most 
vaccine prototypes were aimed at rapidly activating CD4+ 
T-cells after HIV-1 infection. However, because CD4+ T-cells 
are themselves the privileged target of HIV-1, their fast activa-
tion in the presence of the virus might instead facilitate HIV 
replication (38).
Interestingly, the present findings provide a mechanistic 
background for our recent observation in SIV-infected Chinese 
macaques (39, 40). In these studies, we have reported that regula-
tory/suppressive CD8+ T-cells induced by an oral vaccine could 
suppress the activation of SIV-positive CD4+ T-cells, prevent 
viral replication in these cells, and protect the animals against 
subsequent SIV challenge. In the present study, we demonstrated 
that a similar population of regulatory/suppressive CD8+ T-cells 
naturally exists, that it can inhibit the activation of HIV-1-infected 
cells and allow the persistent suppression of HIV-1 replication 
in human ECs. A difference with the animal model, however, is 
the fact that suppressive CD8+ T-cells developed by vaccinated 
Chinese macaques were MHC-1B-E restricted, while the role of 
HLA-E restriction seems less clear in human ECs (Figure S1 in 
Supplementary Material). Whether such a discrepancy results 
from a distinct epitope associated with the mAbs we used remains 
to be determined. Of note in this context that the regulatory/
suppressive CD8+ T-cells (and their resulting in  vivo protec-
tion) observed in vaccinated macaques of Chinese origin have 
neither been found in macaques of North China origin (data not 
shown) nor in those of Indian origin (G. Silvestri, Cent Gardes 
conference: HIV vaccines, Annecy, France, October 25–27, 2015) 
similarly immunized.
In conclusion, we have reported that in most ECs, the prin-
cipal mechanisms of suppression of HIV-1 replication depend 
on specific genetic features regulating the interaction of effector 
CD8+ T-cells with target-infected CD4+ T-cells. Taken together 
with the observation that regulatory/suppressive CD8+ T-cells are 
generated in vaccinated Chinese macaques (39, 40), these data 
provide a major input for the design of an effective HIV-1 vaccine 
in humans.
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